Orencia and Forteo in a group of formal approvals in Japan
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's co-stimulation modulator of T-cell activation, Orencia (abatacept), and Lilly's parathyroid hormone agonist, Forteo (teriparatide), are part of a group of new approvals in Japan which also includes Pfizer's kidney cancer drug, Torisel (temsirolimus).